Infirmary Health Adopts Omnicell's Sterile Compounding Solutions and Services

Ärzte in einem Operationssaal (Symbolbild). © FangXiaNuo / E+ / Getty Images http://www.gettyimages.de/

PR Newswire

MOUNTAIN VIEW, Calif., March 14, 2018

MOUNTAIN VIEW, Calif., March 14, 2018 /PRNewswire/ -- Omnicell, Inc. (NASDAQ: OMCL) today announced that Infirmary Health, a five-hospital health system in Alabama, has chosen Omnicell^® IV solutions to support their sterile compounding operation, helping enhance patient safety and reduce pharmacy outsourcing costs. Infirmary Health will be implementing three i.v.STATION^TM Non-hazardous Compounding Robots and Omnicell's new IVX Workflow technology, part of the Company's industry-leading medication management automation platform, in four hospitals across the health system. Additionally, the system will leverage Omnicell's Robotic IV Insourcing Solution (RIIS™), a comprehensive, turnkey approach to insourcing the hospital's sterile compounding.

Omnicell, Inc. logo. (PRNewsFoto/Omnicell, Inc.)

IV medication safety is a top priority for many hospital leaders, who are working to mitigate safety concerns associated with sterile compounding. According to Pharmacy Purchasing & Products' State of Pharmacy Compounding 2017, 44 percent of healthcare facilities expect to see an increase in in-house compounding volumes over the next three years.¹

Seeking opportunities to enhance outcomes and achieve greater efficiencies led Infirmary Health to identify Omnicell's robotics and workflow automation solutions to achieve operational goals while enhancing patient safety. The health system will implement these technologies later this year.

Through RIIS, a partnership that combines advanced robotic technology, data, and expertly trained pharmacy technician support staff, the pharmacy gains the tools and resources needed to create a safer, more accurate and ultimately more cost-effective IV compounding operation.

"Leveraging IV robotics and workflow solutions will enhance patient safety and improve efficiency across our facilities," said Lee Ann Cain, RPh, vice president, Pharmacy Services, Infirmary Health. "As a strategic partner in this systemwide initiative, Omnicell provides continual support to help us achieve our key performance goals."

"Automating sterile compounding will help Infirmary Health's efforts in creating a safer, more accurate and most cost-effective IV pharmacy," said Douglas Descalzi, vice president and general manager of IV Solutions at Omnicell. "We look forward to continued partnership to enhance control, efficiency and outcomes."

ARIVA.DE Börsen-Geflüster

Kurse

Omnicell

26,73 $

-0,56%

About Infirmary Health

Infirmary Health is the largest non-governmental health care system in the state of Alabama. It serves an 11-county area of south Alabama and north Escambia County, Florida, with 700 active physicians on the medical staff and more than 5,600 employees. Infirmary Health is composed of five acute care hospitals, three post-acute facilities, a physician clinic network with more than 30 locations, six diagnostic imaging centers, two full service breast centers and a freestanding emergency department, along with other affiliated entities.

About Omnicell

Since 1992, Omnicell (NASDAQ: OMCL) has been inspired to create safer and more efficient ways to manage medications and supplies across all care settings. Omnicell is revolutionizing the patient medication experience from hospital to home by empowering providers to keep each patient at the center of care. The Company's autonomous approach to medication management leverages a differentiated platform for hardware and workflow software solutions, real-time predictive intelligence, and performance-driven partnerships to help drive operational, financial, and clinical success for customers.

Supporting the highest level of patient safety is essential to excellent patient care. As a leader in medication and supply dispensing automation, central pharmacy automation, IV robotics, analytics software, and medication adherence and packaging systems, Omnicell is focused on delivering solutions for medication availability, affordability, safety, and adherence. Over 4,000 customers worldwide use Omnicell® automation and analytics solutions to increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety.

Omnicell's innovative medication adherence solutions, used by over 32,000 institutional and retail pharmacies in North America and the United Kingdom, are designed to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions.

For more information about Omnicell, Inc. please visit www.omnicell.com.

OMCL-G

Footnotes:
¹ Pharmacy Purchasing & Products, "State of Pharmacy Compounding 2017," April 2017. https://www.pppmag.com/digitalmag/Main.php?MagNo=185&PageNo=1#page/1

Editor's Notes:

All Omnicell news releases (financial, acquisitions, products, technology etc.) are issued exclusively by PR Newswire and are immediately thereafter posted on the company's external website, omnicell.com.
Omnicell and the Omnicell logo design are registered trademarks of Omnicell, Inc.
All other brand or product names may be trademarks or registered trademarks of their respective companies.

View original content with multimedia:http://www.prnewswire.com/news-releases/infirmary-health-adopts-omnicells-sterile-compounding-solutions-and-services-300613788.html

SOURCE Omnicell, Inc.

Mehr Nachrichten zur Omnicell Aktie kostenlos abonnieren

E-Mail-Adresse

Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.